Related Experiment Video
Updated: Feb 26, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Superantigen staphylococcal enterotoxin C1 inhibits the growth of bladder cancer
1a Department of Urology , The First Affiliated Hospital of China Medical University , Shenyang , People's Republic of China.
Abstract:
Superantigens can induce cell-mediated cytotoxicity preferentially against MHC II-positive target cells with large amounts of inflammatory cytokines releasing. In this study, superantigen staphylococcal enterotoxin C (SEC) 1 was investigated to evaluate its potential in bladder cancer immunotherapy in vitro and in vivo. Our results revealed that SEC1 could stimulate the proliferation of human peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner, accompanied with the release of interleukin-2, interferon-γ, and tumor necrosis factor-α, and increased the population of CD4+ T cells and CD8+ T cells. PBMCs stimulated by SEC1 could initiate significant cytotoxicity towards human bladder cancer cells in vitro. The results of in vivo antitumor experiment indicated that SEC1 could decrease the rate of tumor formation and prolong the survival time of tumor-bearing mice. Our study demonstrated that SEC1 inhibited the growth of bladder cancer. And it is also suggested that SEC1 may become a candidate for bladder cancer immunotherapy.
Insights
Staphylococcal enterotoxin C (SEC1) shows promise for bladder cancer immunotherapy. This superantigen stimulates immune cells to effectively target and inhibit bladder cancer growth in vitro and in vivo.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Superantigens induce cell-mediated cytotoxicity against MHC II-positive cells.
- Inflammatory cytokine release is a key feature of superantigen activity.
Purpose of the Study:
- To investigate the potential of staphylococcal enterotoxin C (SEC1) as a bladder cancer immunotherapy agent.
- To evaluate SEC1's efficacy in vitro and in vivo.
Main Methods:
- Stimulation of human peripheral blood mononuclear cells (PBMCs) with SEC1.
- Assessment of T cell proliferation and cytokine release (IL-2, IFN-γ, TNF-α).
- In vitro cytotoxicity assays against bladder cancer cells and in vivo antitumor experiments.
Main Results:
- SEC1 dose-dependently stimulated PBMC proliferation and cytokine release.
- SEC1 increased CD4+ and CD8+ T cell populations.
- SEC1-stimulated PBMCs exhibited significant cytotoxicity against bladder cancer cells.
- In vivo studies showed SEC1 decreased tumor formation and prolonged survival in tumor-bearing mice.
Conclusions:
- SEC1 demonstrates potent anti-bladder cancer activity.
- SEC1 effectively inhibits bladder cancer growth through immune cell activation.
- SEC1 is a potential candidate for future bladder cancer immunotherapy strategies.
